Bristol-Myers Squibb Q3 Revenue Rises 7% to $13.1B, Full-Year Sales Guidance Raised
nashnova research
Bristol Myers Squibb posted Q3 revenue of $13.1 billion, up 7% year-over-year, beating Wall Street on both top and bottom lines; the company raised its full-year sales guidance but cut its earnings forecast — newer drugs are growing fast, yet the patent cliff on its biggest seller is closing in.
How good is this quarter, really?
Revenue hit $13.1 billion, above the Street's $12.73 billion estimate. Adjusted EPS came in at $1.35, beating the $1.10 consensus by 23%.
Net income was $2.2 billion, roughly flat year-over-year. This means → the top line is accelerating, but the bottom line hasn't caught up yet.
The company flagged that collaboration-related licensing fees dragged on EPS by $0.58 this quarter. In plain terms = strip out that one-time cost, and the profit picture looks meaningfully better than the headline suggests.
Are the new drugs growing fast enough to carry the future?
The growth portfolio delivered 12% year-over-year revenue growth and now accounts for nearly 60% of total sales. This reflects a real shift in the company's revenue center of gravity — from legacy to newer drugs.
Key contributors: Opdivo Qvantig ($334 million in the quarter, above expectations), Breyanzi, Reblozyl, Camzyos, and Opdualag.
Flagship product Eliquis — a blood thinner that prevents clots — generated $4.7 billion, slightly above estimates. But it is expected to face generic competition in the U.S. by 2028.
This means → the new portfolio must close the revenue gap before Eliquis goes off-patent. The window is roughly two years.
Why did the company raise one guidance and cut the other?
Raised: Full-year revenue guidance lifted to $49.75–50.25 billion, above the prior ceiling of $50 billion, citing sustained portfolio momentum.
Cut: Full-year adjusted EPS guidance lowered to $6.35–6.55, down from a prior high of $7.00.
In plain terms = the company is selling more drugs, but partnership-related fees are eating into profit. Higher sales guidance signals an expanding business; lower EPS guidance signals rising near-term costs. The two are not contradictory.
What matters most in the pipeline?
Cobenfy: targets Alzheimer's-related psychosis. Clinical data expected next month at a medical conference.
Milvexian — a next-generation anticoagulant aimed at stroke prevention and atrial fibrillation treatment: results from a secondary stroke-prevention study are expected by year-end; atrial fibrillation data expected in Q1 2027.
This means → the next two quarters are a dense window for pipeline validation. The readouts will directly shape how the market values the company.
What happened with the cell therapy, and how serious is it?
In an early-stage trial of zola-cel — a CAR-T therapy that re-engineers a patient's own immune cells to treat disease — one multiple-sclerosis patient died 44 days after treatment.
The company has voluntarily paused enrollment in its autoimmune CAR-T trials, targeting a restart in early 2027.
Chief Commercialization Officer Adam Lenkowsky still described zola-cel as "a one-time treatment that can deliver deep, durable remission." In plain terms = the company has not abandoned this program, but the safety signal needs time to digest and near-term timelines will slow.
What should investors focus on?
Near term: whether Cobenfy and milvexian clinical data deliver — these are the hard checkpoints for pipeline valuation.
Medium term: whether the growth portfolio can close the revenue gap before Eliquis loses patent protection in 2028.
This means → Bristol Myers Squibb is in a critical "old-to-new" transition window. The quarterly numbers look solid, but the real test plays out over the next two years.
市场有风险，内容仅供研究参考，不构成投资建议。